FR10C0050I2 - OPGL ANTIBODIES - Google Patents

OPGL ANTIBODIES

Info

Publication number: FR10C0050I2
Authority: FR; France
Prior art keywords: opgl antibodies; opgl; antibodies
Prior art date: 2001-06-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR10C0050C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amgen Inc

Amgen Fremont Inc

Original Assignee

Amgen Inc

Amgen Fremont Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-26

Filing date

2010-11-25

Publication date

2011-12-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23162250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0050(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-25 Application filed by Amgen Inc, Amgen Fremont Inc filed Critical Amgen Inc

2011-01-14 Publication of FR10C0050I1 publication Critical patent/FR10C0050I1/fr

2011-12-30 Application granted granted Critical

2011-12-30 Publication of FR10C0050I2 publication Critical patent/FR10C0050I2/en

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Mycology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Oncology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Physics & Mathematics (AREA)

FR10C0050C 2001-06-26 2010-11-25 OPGL ANTIBODIES Active FR10C0050I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30117201P	2001-06-26	2001-06-26
PCT/US2002/020181 WO2003002713A2 (en)	2001-06-26	2002-06-25	Antibodies to opgl

Publications (2)

Publication Number	Publication Date
FR10C0050I1 FR10C0050I1 (en)	2011-01-14
FR10C0050I2 true FR10C0050I2 (en)	2011-12-30

Family

ID=23162250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR10C0050C Active FR10C0050I2 (en)	2001-06-26	2010-11-25	OPGL ANTIBODIES

Country Status (33)

Country	Link
US (8)	US7364736B2 (en)
EP (5)	EP2295081B1 (en)
JP (13)	JP4212470B2 (en)
KR (2)	KR101038585B1 (en)
CN (2)	CN103232539B (en)
AR (1)	AR034637A1 (en)
AT (1)	ATE464068T1 (en)
AU (2)	AU2002320157C1 (en)
BR (1)	BRPI0210579B8 (en)
CA (1)	CA2451955C (en)
CY (5)	CY1110196T1 (en)
DE (2)	DE60235989D1 (en)
DK (4)	DK2270052T3 (en)
EA (1)	EA021242B9 (en)
ES (5)	ES2907826T3 (en)
FR (1)	FR10C0050I2 (en)
IL (3)	IL159512A0 (en)
LU (1)	LU91757I2 (en)
ME (2)	ME00232B (en)
MX (1)	MXPA04000134A (en)
MY (1)	MY143582A (en)
NO (5)	NO345566B1 (en)
NZ (4)	NZ616594A (en)
PH (2)	PH12012502439A1 (en)
PL (1)	PL222211B1 (en)
PT (4)	PT2270052T (en)
RS (1)	RS54274B1 (en)
SG (3)	SG10201603108QA (en)
TR (3)	TR201900581T4 (en)
TW (2)	TWI276443B (en)
WO (1)	WO2003002713A2 (en)
YU (1)	YU103003A (en)
ZA (1)	ZA200400521B (en)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL117175A (en) *	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
DE951551T1 (en)	1996-12-23	2000-09-14	Immunex Corp., Seattle	LIGAND FOR RECEPTOR ACTIVATOR OF NF-KAPPA B, LIGAND IS A MEMBER OF THE TNF SUPERFAMILY
ES2263204T5 (en)	1997-04-15	2013-10-14	Daiichi Sankyo Company, Limited	New protein and process to produce the same
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
RO128635A2 (en)	1997-04-16	2013-07-30	Amgen Inc.	Antibody and fragment thereof binding to opgbp and use thereof, use of soluble form of odar and method for identifying a compound reducing the opgbp activity
EP2009025B1 (en)	1998-05-14	2011-07-27	Immunex Corporation	Method of inhibiting osteoclast activity
US20030103978A1 (en) *	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
US8113839B2 (en)	2000-07-21	2012-02-14	Sony Corporation	Information processing apparatus, information processing method, information processing system, and storage medium
DE01973455T1 (en)	2000-09-22	2004-04-22	Immunex Corp., Seattle	SCREENING PROCEDURE FOR AGONISTS AND ANTAGONISTS OF THE RECEPTOR ACTIVATOR OF NF-KAPPA B
UY27087A1 (en)	2001-01-05	2002-06-20	Pfizer	ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR
DK2270052T3 (en) *	2001-06-26	2018-07-02	Amgen Inc	Antibodies to OPGL
JP4761710B2 (en) *	2002-04-05	2011-08-31	アムジェンインコーポレイテッド	Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
ES2558303T3 (en)	2002-09-11	2016-02-03	Chugai Seiyaku Kabushiki Kaisha	Protein Purification Method
EP1479695B1 (en) *	2003-05-14	2010-02-17	Kenta Biotech AG	Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
CN1838968A (en)	2003-08-08	2006-09-27	艾伯吉尼斯公司	Antibodies aimed to parathyroid hormone (PTH) and uses thereof
US7318925B2 (en) *	2003-08-08	2008-01-15	Amgen Fremont, Inc.	Methods of use for antibodies against parathyroid hormone
DE602004006157T2 (en) *	2003-11-05	2008-01-03	Ares Trading S.A.	PROCESS FOR PURIFYING IL-18 BINDING PROTEIN
TWI359026B (en) *	2004-02-12	2012-03-01	Sankyo Co	Pharmaceutical composition for the osteoclast rela
AU2005267722B2 (en)	2004-08-04	2009-10-08	Amgen Inc.	Antibodies to Dkk-1
WO2006047380A2 (en) *	2004-10-22	2006-05-04	Amgen, Inc.	Method and media for single cell serum-fee culture of cho cells
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
CN101218247A (en) *	2005-04-11	2008-07-09	米德列斯公司	Protein Purification Using HCIC and Ion Exchange Chromatography
WO2006138181A2 (en)	2005-06-14	2006-12-28	Amgen Inc.	Self-buffering protein formulations
AU2015242973C1 (en) *	2005-06-14	2018-07-05	Amgen Inc.	Self-buffering protein formulations
EP1909838A2 (en) *	2005-07-29	2008-04-16	Amgen Inc.	Formulations that inhibit protein aggregation
PE20070684A1 (en) *	2005-11-14	2007-08-06	Amgen Inc	RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
US8168181B2 (en)	2006-02-13	2012-05-01	Alethia Biotherapeutics, Inc.	Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (en) †	2006-02-13	2022-07-25	Daiichi Sankyo Co Ltd	POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES INVOLVED IN THE BONE MODELING PROCESS
CA2650676C (en) *	2006-04-28	2016-03-22	Kyoritsu Seiyaku Corporation	Feline cell capable of being cultured without animal-derived protein, and method for producing virus and method for producing vaccine using thereof
CA2661748C (en)	2006-08-28	2016-02-09	Alex Eon-Duval	Process for the purification of fc-containing proteins
FI3345607T3 (en) *	2006-12-29	2022-11-30		Methods of altering bone growth by administration of sost or wise antagonist or agonist
MX2009010179A (en) *	2007-03-22	2010-03-15	Imclone Llc	Stable antibody formulations.
MX2009012650A (en) *	2007-05-24	2010-02-18	Ablynx Nv	Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders.
CN101802008B (en)	2007-08-21	2015-04-01	安美基公司	Human C-FMS antigen binding proteins
JP5963341B2 (en) *	2007-09-14	2016-08-10	アムジエン・インコーポレーテツド	Homogeneous antibody population
EP2205280B1 (en)	2007-09-27	2019-09-04	Amgen Inc.	Pharmaceutical formulations
SG10201605897RA (en) *	2007-10-11	2016-09-29	Daiichi Sankyo Co Ltd	ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
EP2219602A1 (en)	2007-11-15	2010-08-25	Amgen, Inc	Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
DK2250251T3 (en)	2008-01-09	2018-01-22	Sartorius Stedim Cellca Gmbh	Improved culture medium additive and method of using it
CN102202643A (en) *	2008-02-07	2011-09-28	安姆根有限公司	Stabilized protein compositions
TW201019959A (en) *	2008-08-19	2010-06-01	Regeneron Pharma	Human antibodies to human RANKL
JP2012518400A (en)	2009-02-24	2012-08-16	グラクソグループリミテッド	Multivalent and / or multispecific RANKL binding constructs
JP2012518398A (en)	2009-02-24	2012-08-16	グラクソグループリミテッド	Antigen binding construct
CA2753332A1 (en)	2009-02-24	2010-09-02	Glaxo Group Limited	Antigen-binding constructs
MX2011007342A (en) *	2009-04-09	2011-07-21	Daiichi Sankyo Co Ltd	ANTI-Siglec-15 ANTIBODY.
CA2778105C (en)	2009-10-23	2019-04-02	Amgen Inc.	Vial adapter and system
ES2916399T3 (en)	2010-02-01	2022-06-30	Rebiotix Inc	Bacteriotherapy for Clostridium difficile colitis
CA2800919C (en)	2010-06-07	2019-01-15	Amgen Inc.	Drug delivery device
JP5699030B2 (en) *	2010-07-05	2015-04-08	Ａｘｉｓ株式会社	A therapeutic agent for fibromyalgia containing etanercept
BR112013008255A2 (en)	2010-10-05	2018-09-25	Daiichi Sankyo Co Ltd	isolated antibody or functional fragment thereof, use of an isolated antibody or functional fragment thereof, pharmaceutical composition, polynucleotide, vector, transformed cell, and method for producing antibody
EP3091085B1 (en)	2010-10-06	2019-02-27	Institució Catalana de Recerca I Estudis Avançats	Method of designing a therapy for breast cancer metastasis
WO2012135315A1 (en)	2011-03-31	2012-10-04	Amgen Inc.	Vial adapter and system
AU2012245231B2 (en)	2011-04-20	2016-10-13	Amgen Inc.	Autoinjector apparatus
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR102072250B1 (en)	2011-05-27	2020-03-02	아블린쓰 엔.브이.	Inhibition of bone resorption with rankl binding peptides
EA030868B1 (en)	2011-10-14	2018-10-31	Эмджен Инк.	Injector and method of assembly thereof
SG10201604104PA (en)	2011-10-25	2016-07-28	Prothena Therapeutics Ltd	Antibody formulations and methods
JP6284181B2 (en) *	2012-02-09	2018-02-28	国立研究開発法人理化学研究所	Method for producing circular RNA and protein
NZ631509A (en)	2012-03-30	2016-09-30	Daiichi Sankyo Co Ltd	Cdr-modified anti-siglec-15 antibody
EP2650682A1 (en)	2012-04-09	2013-10-16	Fundació Privada Institut de Recerca Biomèdica	Method for the prognosis and treatment of cancer metastasis
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
EP2856159A4 (en) *	2012-06-01	2016-04-13	Momenta Pharmaceuticals Inc	Methods related to denosumab
BR112014030750A2 (en)	2012-06-06	2017-08-22	Inst Catalana Recerca Estudis Avancats	METHOD FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER METASTASIS
US9493562B2 (en)	2012-07-19	2016-11-15	Alethia Biotherapeutics Inc.	Anti-Siglec-15 antibodies
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
EP2890782A1 (en)	2012-09-02	2015-07-08	AbbVie Inc.	Methods to control protein heterogeneity
PE20191815A1 (en)	2012-09-07	2019-12-27	Coherus Biosciences Inc	STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB
US10119171B2 (en)	2012-10-12	2018-11-06	Inbiomotion S.L.	Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20140105918A1 (en)	2012-10-12	2014-04-17	Inbiomotion S.L.	Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
EP3072548B1 (en)	2012-11-21	2019-03-06	Amgen, Inc	Drug delivery device
EP2948553B1 (en)	2013-01-25	2020-04-01	Baylor College Of Medicine	A helper-dependent adenoviral gene therapy delivery and expression system
HK1207960A1 (en)	2013-03-12	2016-02-19	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en)	2013-03-14	2014-09-25	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2906394A1 (en)	2013-03-15	2014-09-18	Fundacio Institut De Recerca Biomedica (Irb Barcelona)	Method for the prognosis and treatment of cancer metastasis
WO2014149067A1 (en)	2013-03-15	2014-09-25	Momenta Pharmaceuticals, Inc.	Methods related to ctla4-fc fusion proteins
CN105142695B (en)	2013-03-15	2020-06-02	安进公司	Body contour adaptable autoinjector device
ES2973257T3 (en)	2013-03-15	2024-06-19	Amgen Inc	Drug cassette, autoinjector and autoinjector system
EP3593839A1 (en)	2013-03-15	2020-01-15	Amgen Inc.	Drug cassette
US20160032399A1 (en)	2013-03-15	2016-02-04	Inbiomotion S.L.	Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
CA2897825C (en)	2013-03-22	2022-05-24	Scott R. Gibson	Injector and method of assembly
EP2996772B1 (en)	2013-05-13	2018-12-19	Momenta Pharmaceuticals, Inc.	Methods for the treatment of neurodegeneration
US9481901B2 (en)	2013-05-30	2016-11-01	Amgen Inc.	Methods for increasing mannose content of recombinant proteins
US9782445B2 (en)	2013-06-05	2017-10-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en)	2013-06-05	2017-07-04	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en)	2013-06-05	2019-08-20	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
AU2014275025B2 (en)	2013-06-05	2016-12-01	Ferring Microbiome Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
CN105555291B (en)	2013-08-07	2021-08-24	助育公司	Antibodies, compounds and derivatives thereof for the treatment of male infertility
TW201605896A (en)	2013-08-30	2016-02-16	安美基股份有限公司	GITR antigen binding proteins
WO2015047994A2 (en) *	2013-09-24	2015-04-02	The Board Of Regentsl Of The University Of Texas System	A novel hormone that promotes bone resorption and uses thereof
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
MX362041B (en)	2013-10-09	2019-01-07	Fundacio Inst De Recerca Biomedica Irb Barcelona	Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer.
WO2015057622A1 (en)	2013-10-16	2015-04-23	Momenta Pharmaceuticals, Inc.	Sialylated glycoproteins
US9085618B2 (en) *	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
AU2014340174B2 (en)	2013-10-24	2019-09-12	Amgen Inc.	Drug delivery system with temperature-sensitive control
US11097055B2 (en)	2013-10-24	2021-08-24	Amgen Inc.	Injector and method of assembly
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
WO2015087187A1 (en)	2013-12-10	2015-06-18	Rinat Neuroscience Corp.	Anti-sclerostin antibodies
ES2729797T3 (en) *	2013-12-20	2019-11-06	Dev Ct Biotechnology	Specific alpha-enolase antibodies and methods of use in cancer therapies
CN103965357B (en) *	2013-12-31	2016-08-17	嘉和生物药业有限公司	A kind of anti-human RANKL antibody
US10994112B2 (en)	2014-02-05	2021-05-04	Amgen Inc.	Drug delivery system with electromagnetic field generator
DK3116891T3 (en)	2014-03-10	2020-05-04	Richter Gedeon Nyrt	Immunoglobulin purification by purification steps
PL3122426T3 (en)	2014-03-28	2023-05-15	Duke University	Treating breast cancer using selective estrogen receptor modulators
CA3193070A1 (en)	2014-05-07	2015-11-12	Amgen Inc.	Autoinjector with shock reducing elements
JP6817074B2 (en)	2014-06-03	2021-01-20	アムジエン・インコーポレーテツド	Controllable drug delivery system and usage
JP6695814B2 (en) *	2014-06-04	2020-05-20	アムジエン・インコーポレーテツド	Methods for harvesting mammalian cell cultures
JP6766040B2 (en)	2014-10-14	2020-10-07	アムジエン・インコーポレーテツド	Lethal injection device with visual and audible indicators
CA2967224C (en)	2014-12-11	2023-08-22	Inbiomotion S.L.	Binding members for human c-maf
JP2017538512A (en)	2014-12-19	2017-12-28	アムジエン・インコーポレーテツド	Drug delivery device including live button or user interface field
EP3848072A1 (en)	2014-12-19	2021-07-14	Amgen Inc.	Drug delivery device with proximity sensor
WO2016133947A1 (en)	2015-02-17	2016-08-25	Amgen Inc.	Drug delivery device with vacuum assisted securement and/or feedback
US10111928B1 (en) *	2015-02-25	2018-10-30	Saint Louis University	Pulsed introduction of low-dose RANKL as a therapy for osteogenesis imperfecta
US10745461B2 (en)	2015-02-25	2020-08-18	Saint Louis University	Pulsed introduction of low-dose RANKL as a therapy for diet-induced atherosclerosis
US10328123B2 (en)	2015-02-25	2019-06-25	Saint Louis University	Pulsed introduction of low-dose RANKL as a therapy for atherosclerosis
ES2905870T3 (en)	2015-02-27	2022-04-12	Amgen Inc	Drug delivery device having a needle guard mechanism with an adjustable threshold resistance to movement of the needle guard
WO2016176665A1 (en)	2015-04-29	2016-11-03	Radius Health, Inc.	Methods of treating cancer
US10799539B2 (en)	2015-06-09	2020-10-13	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en)	2015-06-09	2020-11-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en)	2015-06-09	2021-02-02	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
JP6616431B2 (en)	2015-06-09	2019-12-04	レビオティクスインコーポレイテッド	Method for producing a microbiota recovery treatment (MRT) composition
HU231463B1 (en)	2015-08-04	2024-01-28	Richter Gedeon Nyrt.	Method for increasing the galactose content of recombinant proteins
WO2017027861A1 (en)	2015-08-13	2017-02-16	Amgen Inc.	Charged depth filtration of antigen-binding proteins
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
US11229702B1 (en)	2015-10-28	2022-01-25	Coherus Biosciences, Inc.	High concentration formulations of adalimumab
EP3386573B1 (en)	2015-12-09	2019-10-02	Amgen Inc.	Auto-injector with signaling cap
US11154661B2 (en)	2016-01-06	2021-10-26	Amgen Inc.	Auto-injector with signaling electronics
UA126115C2 (en)	2016-03-08	2022-08-17	Янссен Байотек, Інк.	Gitr antibodies, methods, and uses
US11200298B2 (en)	2016-03-15	2021-12-14	Amgen Inc.	Reducing probability of glass breakage in drug delivery devices
US11071782B2 (en)	2016-04-20	2021-07-27	Coherus Biosciences, Inc.	Method of filling a container with no headspace
WO2017189089A1 (en)	2016-04-29	2017-11-02	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
EP3455142B1 (en)	2016-05-13	2023-08-09	Amgen Inc.	Vial sleeve assembly
US11238150B2 (en)	2016-05-16	2022-02-01	Amgen Inc.	Data encryption in medical devices with limited computational capability
DK3458610T3 (en)	2016-05-25	2021-06-07	Inbiomotion Sl	Therapeutic treatment of breast cancer based on c-MAF status
WO2017209899A1 (en)	2016-06-03	2017-12-07	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en)	2016-07-01	2018-01-04	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
SG11201900200XA (en)	2016-07-14	2019-02-27	Scholar Rock Inc	Tgfb antibodies, methods, and uses
US20190328965A1 (en)	2016-08-17	2019-10-31	Amgen Inc.	Drug delivery device with placement detection
US20180110856A1 (en)	2016-10-21	2018-04-26	Amgen Inc.	Pharmaceutical Formulations and Methods of Making the Same
WO2018081234A1 (en)	2016-10-25	2018-05-03	Amgen Inc.	On-body injector
EP4467565A3 (en)	2016-12-21	2025-03-12	Amgen Inc.	Anti-tnf alpha antibody formulations
EP4374925A3 (en)	2017-01-05	2025-01-15	Radius Pharmaceuticals, Inc.	Polymorphic forms of rad1901-2hcl
MX2019008432A (en)	2017-01-17	2019-11-18	Amgen Inc	Injection devices and related methods of use and assembly.
CA3052204A1 (en)	2017-02-17	2018-08-23	Amgen Inc.	Insertion mechanism for drug delivery device
EP3582825A1 (en)	2017-02-17	2019-12-25	Amgen Inc.	Drug delivery device with sterile fluid flowpath and related method of assembly
JP2020508803A (en)	2017-03-06	2020-03-26	アムジエン・インコーポレーテツド	Drug delivery device with anti-actuation feature
AU2018230546B2 (en)	2017-03-07	2024-03-21	Amgen Inc.	Needle insertion by overpressure
CA3052310A1 (en)	2017-03-09	2018-09-13	Amgen Inc.	Insertion mechanism for drug delivery device
KR20240042212A (en)	2017-03-28	2024-04-01	암겐 인코포레이티드	Plunger rod and syringe assembly system and method
JOP20190255A1 (en)	2017-04-28	2019-10-27	Amgen Inc	Human RANKL antibody formulas, and methods for their use
WO2018204374A1 (en)	2017-05-02	2018-11-08	Merck Sharp & Dohme Corp.	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (en)	2017-05-02	2019-10-31	Merck Sharp & Dohme	Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
AU2018282077B2 (en)	2017-06-08	2023-11-23	Amgen Inc.	Torque driven drug delivery device
WO2018226515A1 (en)	2017-06-08	2018-12-13	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
JP7195276B2 (en)	2017-06-22	2022-12-23	アムジエン・インコーポレーテツド	Collision/shock reduction due to device activation
EP3641861A1 (en)	2017-06-23	2020-04-29	Amgen Inc.	Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en)	2017-07-14	2019-01-17	Amgen Inc.	Needle insertion-retraction system having dual torsion spring system
IL271173B2 (en)	2017-07-21	2024-04-01	Amgen Inc	Gas permeable sealing element for drug container and methods of assembly
MA49676A (en)	2017-07-25	2020-06-03	Amgen Inc	DRUG ADMINISTRATION DEVICE EQUIPPED WITH A CONTAINER ACCESS SYSTEM AND ASSOCIATED ASSEMBLY PROCEDURE
EP4085942A1 (en)	2017-07-25	2022-11-09	Amgen Inc.	Drug delivery device with gear module and related method of assembly
WO2019032482A2 (en)	2017-08-09	2019-02-14	Amgen Inc.	Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (en)	2017-08-18	2019-02-21	Amgen Inc.	Wearable injector with sterile adhesive patch
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
EP3691717B1 (en)	2017-10-04	2023-02-08	Amgen Inc.	Flow adapter for drug delivery device
EP3691716B1 (en)	2017-10-06	2023-11-29	Amgen Inc.	Drug delivery device with interlock assembly and related method of assembly
EP3694578B1 (en)	2017-10-09	2025-09-24	Amgen Inc.	Drug delivery device with drive assembly and related method of assembly
EP3703779A1 (en)	2017-11-03	2020-09-09	Amgen Inc.	Systems and approaches for sterilizing a drug delivery device
US20200261648A1 (en)	2017-11-06	2020-08-20	Amgen Inc.	Drug delivery device with placement and flow sensing
MA50569A (en)	2017-11-06	2020-09-16	Amgen Inc	FILLING-FINISHING UNITS AND ASSOCIATED PROCESSES
EP3706826A1 (en)	2017-11-10	2020-09-16	Amgen Inc.	Plungers for drug delivery devices
MA50903A (en)	2017-11-16	2021-05-12	Amgen Inc	SELF-INJECTOR WITH STALL AND END POINT DETECTION
SG11202003004RA (en)	2017-11-16	2020-04-29	Amgen Inc	Door latch mechanism for drug delivery device
AU2018372762B2 (en)	2017-11-22	2025-08-21	Inbiomotion S.L.	Therapeutic treatment of breast cancer based on c-maf status
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
CN112423844B (en)	2018-07-04	2024-08-13	雷迪厄斯制药公司	Polymorphic forms of RAD1901-2HCL
US12303677B2 (en)	2018-07-24	2025-05-20	Amgen Inc.	Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023451A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Delivery devices for administering drugs
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
CA3103681A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Delivery devices for administering drugs
CA3103105A1 (en)	2018-07-31	2020-02-06	Amgen Inc.	Fluid path assembly for a drug delivery device
WO2020068623A1 (en)	2018-09-24	2020-04-02	Amgen Inc.	Interventional dosing systems and methods
IL281469B2 (en)	2018-09-28	2024-08-01	Amgen Inc	Assembling a memory alloy ejector activation assembly for a drug delivery device
JP2022503983A (en)	2018-10-02	2022-01-12	アムジエン・インコーポレーテツド	Injection system for drug delivery with internal force transmission
EP3860686A1 (en)	2018-10-05	2021-08-11	Amgen Inc.	Drug delivery device having dose indicator
EA202191038A1 (en)	2018-10-15	2021-07-06	Эмджен Инк.	METHOD OF PLATFORM ASSEMBLY FOR MEDICINE DELIVERY DEVICE
KR102848295B1 (en)	2018-10-15	2025-08-20	암젠 인크	Drug delivery device with damping mechanism
MA54057A (en)	2018-11-01	2022-02-09	Amgen Inc	DRUG DELIVERY ELEMENT PARTIAL RETRACTION DRUG DELIVERY DEVICES
TWI831847B (en)	2018-11-01	2024-02-11	美商安進公司	Drug delivery devices with partial needle retraction and methods for operating the same
EP3873566B1 (en)	2018-11-01	2024-11-27	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
HU231514B1 (en)	2018-11-07	2024-07-28	Richter Gedeon Nyrt.	A method for changing the glycosylation pattern of a recombinant glycoprotein produced in cell culture
KR20210089215A (en)	2018-11-07	2021-07-15	머크 샤프 앤드 돔 코포레이션	Co-Formulation of Anti-LAG3 Antibody and Anti-PD-1 Antibody
CN119390714A (en)	2019-02-12	2025-02-07	雷迪厄斯制药公司	Methods and compounds
HU231498B1 (en)	2019-04-04	2024-05-28	Richter Gedeon Nyrt	Development of affinity chromatography of immunoglobulins using pre-binding flocculation
MX2021012557A (en)	2019-04-24	2021-11-12	Amgen Inc	SETS AND METHODS OF VERIFICATION OF STERILIZATION OF SYRINGES.
WO2020222668A1 (en)	2019-04-30	2020-11-05	Instituto de Medicina Molecular João Lobo Antunes	Rank pathway inhibitors in combination with cdk inhibitors
EP4017560A2 (en)	2019-08-23	2022-06-29	Amgen, Inc	Drug delivery device with configurable needle shield engagement components and related methods
WO2021149012A1 (en)	2020-01-24	2021-07-29	Radius Health, Inc.	Methods of stimulating bone growth with abalopartide and denosumab
CN113621060B (en) *	2020-05-07	2023-07-04	浙江瑞硕生物技术有限公司	OPG antibody pair and application thereof
BR112023024278A2 (en)	2021-05-21	2024-01-30	Amgen Inc	METHOD OF OPTIMIZING A FILLING RECIPE FOR A DRUG CONTAINER
WO2024064878A1 (en)	2022-09-23	2024-03-28	The University Of North Carolina At Chapel Hill	Methods and compositions for the treatment of melanoma
WO2024104409A1 (en) *	2022-11-16	2024-05-23	苏州盛迪亚生物医药有限公司	Pharmaceutical composition comprising anti-rankl-ngf bispecific antibodies

Family Cites Families (318)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4338397A (en) *	1980-04-11	1982-07-06	President And Fellows Of Harvard College	Mature protein synthesis
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
EP0088046B1 (en)	1982-02-17	1987-12-09	Ciba-Geigy Ag	Lipids in the aqueous phase
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4755465A (en) *	1983-04-25	1988-07-05	Genentech, Inc.	Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4710457A (en)	1983-06-29	1987-12-01	Sloan-Kettering Institute For Cancer Research	Monoclonal antibody for human hematopoietic glycoproteins and method
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Pharmaceutical composition containing urokinase
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
DE3572982D1 (en)	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
EP0192658A4 (en)	1984-07-30	1987-07-13	Salk Inst For Biological Studi	Retroviral gene transfer vectors.
US4699880A (en)	1984-09-25	1987-10-13	Immunomedics, Inc.	Method of producing monoclonal anti-idiotype antibody
US4760130A (en)	1984-12-06	1988-07-26	Synergen Biologicals, Inc.	Serine protease inhibitors and methods for isolation of same
US5900400A (en)	1984-12-06	1999-05-04	Amgen Inc.	Serine protease inhibitor analogs
JPS6291197A (en)	1985-10-17	1987-04-25	Dainippon Pharmaceut Co Ltd	Anti-human interleukin 1 antibody, its production method and its use
US6150090A (en)	1986-01-09	2000-11-21	Massachusetts Institute Of Technology	Nuclear factors associated with transcriptional regulation
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4935343A (en)	1986-08-08	1990-06-19	Syntex (U.S.A.) Inc.	Monoclonal antibodies for interleukin-1β
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
EP0281604B1 (en)	1986-09-02	1993-03-31	Enzon Labs Inc.	Single polypeptide chain binding molecules
DK590387A (en)	1986-11-13	1988-05-14	Otsuka Pharma Co Ltd	ANTIBODIES AGAINST INTERLEUKIN-1
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
US5359032A (en)	1987-08-26	1994-10-25	Biogen Inc.	Interkeukin-1 inhibitor
IL83878A (en)	1987-09-13	1995-07-31	Yeda Res & Dev	Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en)	1987-09-13	1996-04-30	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising an anticytokine
IL98078A0 (en)	1991-05-07	1992-06-21	Yeda Res & Dev	Pharmaceutical compositions comprising an anticytokyne
US5106627A (en)	1987-11-17	1992-04-21	Brown University Research Foundation	Neurological therapy devices
US4892538A (en)	1987-11-17	1990-01-09	Brown University Research Foundation	In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en)	1987-11-17	1992-10-27	Brown University Research Foundation	Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
WO1989004838A1 (en)	1987-11-25	1989-06-01	Immunex Corporation	Interleukin-1 receptors
US4968607A (en)	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
US5319071A (en)	1987-11-25	1994-06-07	Immunex Corporation	Soluble interleukin-1 receptors
US5846534A (en)	1988-02-12	1998-12-08	British Technology Group Limited	Antibodies to the antigen campath-1
US4942184A (en) *	1988-03-07	1990-07-17	The United States Of America As Represented By The Department Of Health And Human Services	Water soluble, antineoplastic derivatives of taxol
GB8807803D0 (en)	1988-03-31	1988-05-05	Glaxo Group Ltd	Biochemical product
HU215434B (en)	1988-05-27	1999-04-28	Synergen Inc.	Method for Interleukin-1 Inhibitors to Generate DNA Sequences, Vectors, and Host Cells encoding them
US5075222A (en)	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
US5811261A (en)	1988-09-12	1998-09-22	Yeda Research And Development Co. Ltd.	Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US5359037A (en)	1988-09-12	1994-10-25	Yeda Research And Development Co. Ltd.	Antibodies to TNF binding protein I
IL94039A (en)	1989-08-06	2006-09-05	Yeda Res & Dev	Antibodies to tbp - 1 and their use
EP0364778B1 (en)	1988-10-01	1996-03-13	Otsuka Pharmaceutical Co., Ltd.	Antibody against interleukin-1beta
FR2640146B1 (en)	1988-12-08	1993-12-24	Commissariat A Energie Atomique	ANTI-INTERLEUKIN MONOCLONAL ANTIBODIES 1 (ALPHA) AND 1 (BETA), THEIR PRODUCTION METHOD AND APPLICATIONS OF SAID ANTIBODIES TO DETECTION OF INTERLEUKINS 1 (ALPHA) AND 1 (BETA) AND THERAPEUTICS
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DE59010941D1 (en)	1989-04-21	2005-03-24	Amgen Inc	TNF receptor, TNF-binding proteins and DNAs coding therefor
DE3922089A1 (en)	1989-05-09	1990-12-13	Basf Ag	NEW PROTEINS AND THEIR PRODUCTION
DE69017753T3 (en)	1989-05-18	2013-06-20	Yeda Research And Development Co., Ltd.	Tumor necrosis factor binding protein II, its purification and specific antibodies
IL107267A (en)	1993-10-12	2009-07-20	Yeda Res & Dev	Ligand to a member of the tnf/ngf receptor family
AU648505B2 (en)	1989-05-19	1994-04-28	Amgen, Inc.	Metalloproteinase inhibitor
US5627262A (en)	1989-07-05	1997-05-06	The Board Of Regents Of The University Of Oklahoma	Method and composition for the treatment of septic shock
IL95031A (en)	1989-07-18	2007-03-08	Amgen Inc	Method for the production of a human recombinant tumor necrosis factor inhibitor
WO1991003553A1 (en)	1989-09-05	1991-03-21	Immunex Corporation	TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
US5395760A (en)	1989-09-05	1995-03-07	Immunex Corporation	DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (en)	1989-09-12	2006-11-23	Ahp Mfg B V	TFN-binding proteins
JPH03127800A (en)	1989-10-13	1991-05-30	Teijin Ltd	Tumor necrosis factor activity inhibitor
BR9007883A (en)	1989-11-29	1992-09-29	Synergen Inc	PRODUCTION OF RECOMBINANT HUMAN INTERLEUCIN-1 INHIBITOR
DE69022559T2 (en)	1989-12-13	1996-05-02	Yeda Res & Dev	Expression of the recombinant tumor necrosis factor binding protein I (TBP-I).
US5136021A (en)	1990-02-27	1992-08-04	Health Research, Inc.	TNF-inhibitory protein and a method of production
AU649245B2 (en)	1990-04-02	1994-05-19	Amgen, Inc.	Methods for treating interleukin-1 mediated diseases
US6552170B1 (en)	1990-04-06	2003-04-22	Amgen Inc.	PEGylation reagents and compounds formed therewith
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
AU7683391A (en)	1990-04-27	1991-11-27	Upjohn Company, The	Modified interleukin-1 inhibitors
US5872095A (en)	1990-05-01	1999-02-16	Chiron Corporation	IL-1 receptor antagonists medicaments
WO1991017249A1 (en)	1990-05-01	1991-11-14	Cetus Corporation	Interleukin-1 antagonist and uses thereof
US5350683A (en)	1990-06-05	1994-09-27	Immunex Corporation	DNA encoding type II interleukin-1 receptors
GB2246569A (en)	1990-06-15	1992-02-05	Charing Cross Sunley Research	Tumour necrosis factor - alpha binding protein
US7253264B1 (en)	1990-06-28	2007-08-07	Sanofi-Arentideutschland GmbH	Immunoglobulin fusion proteins, their production and use
DE59109269D1 (en)	1990-06-28	2005-12-15	Hoechst Ag	Fusion proteins with immunoglobulin components, their preparation and use
WO1992001002A1 (en)	1990-07-11	1992-01-23	Teijin Limited	Tumor necrosis factor activity inhibitor and production thereof
DE69128627T2 (en)	1990-08-03	1998-07-02	Smithkline Beecham Corp Philad	TNF INHIBITORS
US5840496A (en)	1990-10-09	1998-11-24	Chiron Corporation	Method for diagnosing endometrial cancer
GB9022648D0 (en)	1990-10-18	1990-11-28	Charing Cross Sunley Research	Polypeptide and its use
US5858355A (en)	1990-12-20	1999-01-12	University Of Pittsburgh Of The Commonwealth System Of Higher Education	IRAP gene as treatment for arthritis
NZ314630A (en)	1991-01-17	2000-11-24	Harvard College	Use of trans-splicing ribozymes for genetic modification and cell ablation in a host cell
AU1235692A (en)	1991-01-18	1992-08-27	Synergen, Inc.	Methods for treating tumor necrosis factor mediated diseases
US6565841B1 (en)	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
ATE240740T1 (en)	1991-03-15	2003-06-15	Amgen Inc	PEGYLATION OF POLYPEPTIDES
IL99120A0 (en)	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
EP0611302B1 (en)	1991-10-15	2000-03-29	MULLARKEY, Michael F.	Receptors for treating late phase inflammatory responses
US5961974A (en)	1991-10-25	1999-10-05	Immunex Corporation	Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
EP0667901B2 (en)	1991-10-25	2008-10-15	Immunex Corporation	Novel cytokine
ES2038546B1 (en)	1991-11-08	1994-02-16	Andromaco Lab	PROCEDURE FOR OBTAINING A PRODUCT OF A POLYPEPTIDIC NATURE WITH INHIBITING ACTIVITY OF THE HYPERPRODUCTION OF THE TUMOR NECROSIS FACTOR.
JPH05244982A (en) *	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	Humanized b-b10
EP0746609A4 (en)	1991-12-17	1997-12-17	Genpharm Int	Transgenic non-human animals capable of producing heterologous antibodies
IL104369A0 (en)	1992-01-13	1993-05-13	Smithkline Beecham Corp	Novel compounds and compositions
WO1993015722A1 (en)	1992-02-07	1993-08-19	Syntex (Usa) Inc.	Controlled delivery of pharmaceuticals from preformed porous microparticles
ES2191013T3 (en)	1992-03-04	2003-09-01	Cell Therapeutics Inc	XANTINA COMPOUNDS HYDROXYLATED ENANTIOMERS.
EP0670730B1 (en)	1992-03-30	2003-06-04	Immunex Corporation	Fusion protein comprising two tumor necrosis factor receptors
JPH07509223A (en)	1992-04-30	1995-10-12	アムジェンインコーポレイテッド	Methods for treating interleukin-1-mediated and tumor necrosis factor-mediated diseases
JPH05312248A (en)	1992-05-08	1993-11-22	Nissan Motor Co Ltd	Shift level device
DE4219626A1 (en)	1992-06-16	1993-12-23	Wehling Peter Priv Doz Dr Med	Incorporating therapeutic gene via vector into body cells - in=vivo or in vitro, for subsequent expression and secretion of active protein, partic. for treating degenerative diseases of spine and nerves
JPH0630788A (en)	1992-07-16	1994-02-08	Otsuka Pharmaceut Co Ltd	Recombinant antibody for human interleukin-1
US5545716A (en)	1992-09-08	1996-08-13	University Of Florida	Superantigen agonist and antagonist peptides
HU219445B (en)	1992-09-17	2001-04-28	Amgen Inc.	Stable pharmaceutical compositions and methods for the preparation of interleukin-1 inhibitors
JPH06111399A (en)	1992-09-30	1994-04-22	Sony Corp	Magneto-optical recording medium and manufacturing method thereof
EP0664128A4 (en)	1992-10-07	1997-12-17	Sumitomo Pharma	PHARMACEUTICAL AGENT FOR INHIBITING TUMORNESCROSE FACTOR PRODUCTION.
JP3589665B2 (en)	1992-10-23	2004-11-17	イミュネックス・コーポレーション	Preparation of soluble oligomeric proteins
WO1994009818A1 (en) *	1992-10-30	1994-05-11	The Regents Of The University Of California	Method for stimulating production of variable region gene family restricted antibodies through b-cell superantigen vaccination
US5866576A (en)	1992-12-16	1999-02-02	Cell Therapeutics, Inc.	Epoxide-containing compounds
EP0607776B1 (en)	1993-01-08	1998-12-09	Hoechst Aktiengesellschaft	Use of leflunomid for the inhibition of tumor necrosis factor alpha
ATE204299T1 (en)	1993-03-05	2001-09-15	Bayer Ag	HUMAN MONOCLONAL ANTI-TNF ALPHA ANTIBODIES
CA2157782A1 (en)	1993-03-08	1994-09-15	Joseph C. Glorioso	Gene transfer for treating a connective tissue of a mammalian host
AU6285694A (en)	1993-03-19	1994-10-11	Vacsyn S.A.	Therapeutical compositions for use in humans, characterised by a combination of a muramyl peptide and a cytokine
US6326353B1 (en)	1993-03-23	2001-12-04	Sequus Pharmaceuticals, Inc.	Enhanced circulation effector composition and method
US5843905A (en)	1993-06-04	1998-12-01	Vertex Pharmaceuticals, Incorporated	Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
FR2706772A1 (en)	1993-06-22	1994-12-30	Vacsyn Sa	Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
WO1995001997A1 (en)	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
AU7267094A (en)	1993-07-28	1995-02-28	Rhone-Poulenc Rorer Limited	Compounds as pde iv and tnf inhibitors
NZ276577A (en)	1993-11-29	1997-11-24	Merrell Pharma Inc	2-acyl-4-benzenesulphonyliminoquinoline and -chromene derivatives
CA2138305A1 (en)	1993-12-28	1995-06-29	Naohito Ohashi	Tumor necrosis factor production inhibitors
GB9401460D0 (en)	1994-01-26	1994-03-23	Rhone Poulenc Rorer Ltd	Compositions of matter
US5608035A (en)	1994-02-02	1997-03-04	Affymax Technologies N.V.	Peptides and compounds that bind to the IL-1 receptor
CA2183562A1 (en)	1994-02-18	1995-08-24	J. Peter Klein	Intracellular signalling mediators
JPH09505082A (en)	1994-03-09	1997-05-20	ファイザー・インコーポレーテッド	Isoxazoline as an inhibitor of TNF release
US5708142A (en)	1994-05-27	1998-01-13	Genentech, Inc.	Tumor necrosis factor receptor-associated factors
US5741667A (en)	1994-05-27	1998-04-21	Genentech, Inc.	Tumor necrosis factor receptor-associated factors
US5817822A (en)	1994-06-24	1998-10-06	Novartis Corporation	Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
IL114417A0 (en)	1994-07-07	1995-10-31	Res Dev Foundation	Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use
US5877180A (en)	1994-07-11	1999-03-02	University Of Virginia Patent Foundation	Method for treating inflammatory diseases with A2a adenosine receptor agonists
DE69519454T2 (en)	1994-07-14	2001-05-03	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama	Protein that induces interferon gamma production and monoclonal antibodies against it
US5641747A (en)	1994-07-25	1997-06-24	Temple University-Of The Commonwealth System Of Higher Education	Treatment of osteopetrotic diseases
US5633227A (en)	1994-09-12	1997-05-27	Miles, Inc.	Secretory leukocyte protease inhibitor as an inhibitor of tryptase
IT1269989B (en)	1994-09-21	1997-04-16	Dompe Spa	IL-1 RECEPTOR ANTAGONISTS WITH INCREASED INHIBITORY ACTIVITY
CN1193978A (en)	1994-10-05	1998-09-23	奇罗斯恩有限公司	Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
US5852173A (en)	1994-10-19	1998-12-22	Genetics Institute, Inc.	TNF receptor death ligand proteins and inhibitors of ligand binding
TW581771B (en)	1994-11-15	2004-04-01	Hayashibara Biochem Lab	Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
WO1996019990A1 (en)	1994-12-23	1996-07-04	Smithkline Beecham Corporation	4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
ZA9510826B (en)	1994-12-23	1996-06-20	Smithkline Beecham Corp	3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds
US6323201B1 (en)	1994-12-29	2001-11-27	The Regents Of The University Of California	Compounds for inhibition of ceramide-mediated signal transduction
US6429221B1 (en)	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
KR19980701286A (en)	1995-01-09	1998-05-15	오스카 아키히코	TNF-alpha inhibitor
PE64396A1 (en)	1995-01-23	1997-01-28	Hoffmann La Roche	INTERLEUKIN 1 RECEIVER ACCESSORY PROTEIN
IL117175A (en)	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
US6001349A (en)	1995-02-22	1999-12-14	Therion Biologics Corporation	Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
BR9607336A (en)	1995-02-23	1997-11-25	Novartis Nutrition Ag	Amino acid compositions and their uses in clinical nutrition
WO1996028546A1 (en)	1995-03-15	1996-09-19	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
EP0737471A3 (en)	1995-04-10	2000-12-06	L'oreal	Use of alkaline earth metal salts as TNF-alpha inhibitor in a topical composition and composition obtained therefrom
PT821671E (en)	1995-04-20	2001-04-30	Pfizer	ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS
JPH11507205A (en)	1995-04-27	1999-06-29	ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド	Human tumor necrosis factor receptor
EP0824543A1 (en)	1995-05-10	1998-02-25	Chiroscience Limited	Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
AR004471A1 (en)	1995-05-31	1998-12-16	Smithkline Beecham Corp	CYCLOHEXAN-1-OL-4,4-DISSTITUTED COMPOUNDS, USEFUL IN THE TREATMENT OF ALLERGIC AND INFLAMMATORY DISEASES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
US5817476A (en)	1995-06-07	1998-10-06	Genetics Institute, Inc.	Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
US5843901A (en)	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
IL122174A (en)	1995-06-07	2004-07-25	Immunex Corp	Dna encoding a cd40l mutein and a cd40l polypeptide encoded by said dna
US5739143A (en)	1995-06-07	1998-04-14	Smithkline Beecham Corporation	Imidazole compounds and compositions
US5830742A (en)	1995-06-08	1998-11-03	Immunex Corporation	TNF-α converting enzyme
KR100510234B1 (en)	1995-06-29	2005-11-25	임뮤넥스 코포레이션	Cytokine that Induces Apoptosis
US6127977A (en)	1996-11-08	2000-10-03	Cohen; Nathan	Microstrip patch antenna with fractal structure
ZA966663B (en)	1995-08-17	1998-02-06	Genentech Inc	Traf Inhibitors.
US5728844A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
JPH11511463A (en)	1995-08-31	1999-10-05	スミスクライン・ビーチャム・コーポレイション	Interleukin converting enzyme and apoptosis
IL115245A (en)	1995-09-11	2002-12-01	Yissum Res Dev Co	Tumor necrosis factor inhibiting pharmaceuticals
AU7169296A (en)	1995-09-27	1997-04-17	Board Of Trustees Of The Leland Stanford Junior University	Methods for determining t-cell profiles of immunocompromised subjects
HUP0003760A3 (en)	1995-10-05	2001-05-28	Darwin Discovery Ltd Cambridge	Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation, process for production thereof and their use
DE19540475A1 (en)	1995-10-20	1997-04-24	Schering Ag	Chiral methylphenyloxazolidinones
US6281352B1 (en)	1995-11-14	2001-08-28	Dupont Pharmaceuticals Company	Macrocyclic compounds as metalloprotease inhibitors
CN1202161A (en)	1995-11-14	1998-12-16	杜邦麦克药品公司	Macrocyclic compounds as metalloproteinase inhibitors
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
CO4750805A1 (en) *	1995-12-13	1999-03-31	Sumitomo Chemical Co	SHAMPOO COMPOUND
US5869315A (en)	1995-12-18	1999-02-09	Basf Aktiengesellschaft	Modified interleukin-1β converting enzyme with increased stability
US5990119A (en)	1995-12-21	1999-11-23	Smithkline Beecham Corporation	1,4,4-(trisubstituted)cyclohexane monomers and related compounds
US5891883A (en)	1995-12-21	1999-04-06	Smithkline Beecham Corporation	4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
US5869677A (en)	1995-12-21	1999-02-09	Smithkline Beecham Corporation	3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
US6613544B1 (en) *	1995-12-22	2003-09-02	Amgen Inc.	Osteoprotegerin
US6369027B1 (en)	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin
AU1341797A (en)	1995-12-29	1997-07-28	Incyte Pharmaceuticals, Inc.	Nucleic acids encoding interferon gamma inducing factor-2
US6046048A (en)	1996-01-09	2000-04-04	Genetech, Inc.	Apo-2 ligand
DK0929578T3 (en)	1996-02-09	2003-08-25	Abbott Lab Bermuda Ltd	Human antibodies that bind human TNFalfa
CN1215340A (en)	1996-02-09	1999-04-28	安姆根有限公司	Composition comprising interleukin-1 inhibitor and release-controlling polymer
US5994351A (en)	1998-07-27	1999-11-30	Pfizer Inc.	Arylsulfonylamino hydroxamic acid derivatives
US5981220A (en)	1996-03-27	1999-11-09	Human Genome Sciences, Inc.	Epidermal differentiation factor
GB9607120D0 (en)	1996-04-04	1996-06-12	Chiroscience Ltd	Compounds
GB9607119D0 (en)	1996-04-04	1996-06-12	Chiroscience Ltd	Compounds
GB9607249D0 (en)	1996-04-04	1996-06-12	Chiroscience Ltd	Compounds
US5710013A (en)	1996-04-19	1998-01-20	Tularik Inc.	Tumor necrosis factor receptor associated factor 6 (TRAF6)
GB9609795D0 (en)	1996-05-10	1996-07-17	Smithkline Beecham Plc	Novel compounds
AUPO048296A0 (en)	1996-06-14	1996-07-11	Fujisawa Pharmaceutical Co., Ltd.	New compound and its preparation
EP1669454A3 (en)	1996-06-27	2009-04-01	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
DE69700616T2 (en)	1996-07-02	2000-03-16	Nisshin Flour Milling Co., Ltd.	Imide derivatives
TW555765B (en)	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5853977A (en)	1996-07-12	1998-12-29	Schering Corporation	Mammalian TNF-α convertases
JPH10130149A (en)	1996-07-12	1998-05-19	Sankyo Co Ltd	TNF production inhibitor
US5877222A (en)	1996-07-19	1999-03-02	The Regents Of The University Of California	Method for treating aids-associated dementia
GB9616643D0 (en)	1996-08-08	1996-09-25	Chiroscience Ltd	Compounds
ATE418536T1 (en)	1996-08-12	2009-01-15	Celgene Corp	NEW IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN REDUCING CYTOKINE LEVELS
US6069132A (en)	1996-08-14	2000-05-30	Revanker; Ganapathi R.	Phosphazole compounds
WO1998013348A1 (en)	1996-09-25	1998-04-02	Ss Pharmaceutical Co., Ltd.	Substituted vinylpyridine derivatives and drugs containing the same
US5962481A (en)	1996-10-16	1999-10-05	American Cyanamid Company	Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
GB9621859D0 (en)	1996-10-21	1996-12-11	Xenova Ltd	Cytokine production inhibitors
GB9712761D0 (en)	1997-06-17	1997-08-20	Chiroscience Ltd	Quinolines and their therapeutic use
JPH10147531A (en)	1996-11-19	1998-06-02	Otsuka Pharmaceut Co Ltd	Tnf-alpha production inhibitor
CA2271963A1 (en)	1996-11-20	1998-05-28	Linda L. Chang	Triaryl substituted imidazoles, compositions containing such compounds and methods of use
US5955480A (en)	1996-11-20	1999-09-21	Merck & Co., Inc.	Triaryl substituted imidazoles, compositions containing such compounds and methods of use
US5834435A (en)	1996-11-27	1998-11-10	Slesarev; Vladimir I.	Inhibition of TNF-α pleiotropic and cytotoxic effects
EP1500329B1 (en)	1996-12-03	2012-03-21	Amgen Fremont Inc.	Human antibodies that specifically bind human TNF alpha
PT942740E (en)	1996-12-06	2004-01-30	Amgen Inc	COMBINATION THERAPY USING A TNF LIGACTION PROTEIN FOR TREATMENT OF TNF-MEDIATED DISEASES
DE122010000046I1 (en)	1996-12-13	2011-05-05	Schering Corp	Surface antigens from mammals
DE19652227A1 (en)	1996-12-16	1998-06-18	Bosch Gmbh Robert	Method and device for assigning a remote control to a base station
JPH10231285A (en)	1996-12-17	1998-09-02	Ishihara Sangyo Kaisha Ltd	Phthalimide derivative or its salt, their production and pharmaceutical composition containing the derivative
AU5901598A (en)	1996-12-20	1998-07-17	Board Of Regents, The University Of Texas System	Compositions and methods of use for osteoclast inhibitory factors
US6271349B1 (en)	1996-12-23	2001-08-07	Immunex Corporation	Receptor activator of NF-κB
DE951551T1 (en)	1996-12-23	2000-09-14	Immunex Corp., Seattle	LIGAND FOR RECEPTOR ACTIVATOR OF NF-KAPPA B, LIGAND IS A MEMBER OF THE TNF SUPERFAMILY
US7141393B2 (en)	1996-12-26	2006-11-28	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18-receptor proteins
PT853083E (en)	1997-01-06	2001-12-28	Pfizer	COMPOSITION OF PYRIDILFURANE AND PYRIDYLTHOPHENE AND ITS PHARMACEUTICAL UTILIZATION
US5952320A (en)	1997-01-07	1999-09-14	Abbott Laboratories	Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en)	1997-01-07	1998-07-02	Abbott Lab	C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US6054559A (en)	1997-01-28	2000-04-25	Smithkline Beecham Corporation	Interleukin-1 receptor antagonist beta (IL-1raβ)
EP0964849B1 (en)	1997-01-29	2003-06-04	Pfizer Inc.	Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
JP3955352B2 (en)	1997-02-25	2007-08-08	株式会社林原生物化学研究所	Osteoclast formation inhibitor
US5969102A (en)	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
WO1998039326A1 (en)	1997-03-04	1998-09-11	Monsanto Company	Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
ES2209122T3 (en)	1997-03-04	2004-06-16	Pharmacia Corporation	AULMA HYDROXAMIC HYDROXAMIC SULFONIL ACID COMPOUNDS.
US6476027B1 (en)	1997-03-04	2002-11-05	Monsanto Company	N-hydroxy 4-sulfonyl butanamide compounds
ATE287885T1 (en)	1997-03-04	2005-02-15	Pharmacia Corp	HYDROXAMIC ACID SULFONAMIDE DERIVATIVES WITH AMIDATED AROMATIC RING
US6638952B1 (en)	1997-03-04	2003-10-28	Pharmacia Corporation	Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6087116A (en)	1997-03-12	2000-07-11	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18 (IL-18) receptor polypeptides and their uses
JPH10259140A (en)	1997-03-18	1998-09-29	Sumitomo Pharmaceut Co Ltd	Tumor necrosis factor production inhibitor
US6054487A (en)	1997-03-18	2000-04-25	Basf Aktiengesellschaft	Methods and compositions for modulating responsiveness to corticosteroids
SI20110A (en)	1997-03-18	2000-06-30	Basf Aktiengesellschaft	Methods and compositions for modulating responsiveness to corticosteroids
WO1998042325A2 (en)	1997-03-21	1998-10-01	Cistron Biotechnology, Inc.	INHIBITION OF THE CLEAVAGE OF PRECURSOR IL-1$g(b)
GB9706255D0 (en)	1997-03-26	1997-05-14	Smithkline Beecham Plc	Novel compounds
JP2001517225A (en)	1997-03-28	2001-10-02	ゼネカリミテッド	Process for the preparation of N- (3-hydroxy-succinyl) -amino acid derivatives
AU6843298A (en)	1997-03-28	1998-10-22	Zeneca Limited	Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor
CA2285548C (en)	1997-04-04	2006-07-11	Pfizer Products Inc.	Nicotinamide derivatives
US6297248B1 (en)	1997-04-06	2001-10-02	Suntory Limited	1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor
ATE297755T1 (en)	1997-04-10	2005-07-15	Agennix Inc	USE OF LACTOFERRIN IN THE TREATMENT OF CONDITIONS CAUSED BY ALLERGENS
ES2263204T5 (en)	1997-04-15	2013-10-14	Daiichi Sankyo Company, Limited	New protein and process to produce the same
EP0977851A2 (en)	1997-04-15	2000-02-09	Genetics Institute, Inc.	Secreted proteins and polynucleotides encoding them
US6316408B1 (en) *	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
RO128635A2 (en)	1997-04-16	2013-07-30	Amgen Inc.	Antibody and fragment thereof binding to opgbp and use thereof, use of soluble form of odar and method for identifying a compound reducing the opgbp activity
US5843678A (en)	1997-04-16	1998-12-01	Amgen Inc.	Osteoprotegerin binding proteins
FR2762315B1 (en)	1997-04-22	1999-05-28	Logeais Labor Jacques	AMINO ACID DERIVATIVES INHIBITOR OF EXTRACELLULAR MATRIX METALLOPROTEASES AND TNF ALPHA RELEASE
AU7138298A (en)	1997-04-24	1998-11-13	Ortho-Mcneil Corporation, Inc.	Substituted imidazoles useful in the treatment of inflammatory diseases
CA2229449A1 (en)	1997-04-25	1998-10-25	Takeda Chemical Industries, Ltd.	Novel receptor protein and its use
FR2762514B1 (en)	1997-04-29	1999-10-22	Sanofi Sa	USE OF TETRAHYDROPYRIDINE DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES LEADING TO DEMYELINATION
JP3776203B2 (en)	1997-05-13	2006-05-17	第一製薬株式会社	ICAM-1 production inhibitor
EP0983260A2 (en)	1997-05-22	2000-03-08	G.D. Searle & Co.	3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
WO1998054201A1 (en)	1997-05-29	1998-12-03	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like protein 8
US6265535B1 (en)	1997-05-30	2001-07-24	The Trustees Of The University Of Pennsylvania	Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
JPH111481A (en)	1997-06-10	1999-01-06	Sumitomo Pharmaceut Co Ltd	Piperidinyl phthalazine derivative
HUP0003309A3 (en)	1997-06-12	2002-02-28	Rhone Poulenc Rorer Ltd West M	Imidazolyl-cyclic acetals, process for producing them and pharmaceutical compositions containing the same
KR19990001101A (en)	1997-06-12	1999-01-15	손경식	Catechol amino acid derivatives, preparation methods thereof and pharmaceutical compositions containing the same
WO1998056377A1 (en)	1997-06-13	1998-12-17	Smithkline Beecham Corporation	Novel pyrazole and pyrazoline substituted compounds
JPH119269A (en)	1997-06-19	1999-01-19	Kaken Pharmaceut Co Ltd	Osteoclast cells
GB9713732D0 (en)	1997-06-27	1997-09-03	Pharmacia & Upjohn Spa	Substituted triazinic compounds
GB9713733D0 (en)	1997-06-27	1997-09-03	Pharmacia & Upjohn Spa	Poly-branched polycarboxamido compounds
EP0994858A1 (en)	1997-06-30	2000-04-26	Ortho-McNeil Pharmaceutical, Inc.	2-substituted imidazoles useful in the treatment of inflammatory diseases
US6235787B1 (en)	1997-06-30	2001-05-22	Hoffmann-La Roche Inc.	Hydrazine derivatives
GB9713726D0 (en)	1997-06-30	1997-09-03	Ciba Geigy Ag	Organic compounds
US5843721A (en)	1997-07-03	1998-12-01	Tularik Inc.	Nucleic acids encoding human NIK protein
WO1999001139A1 (en)	1997-07-03	1999-01-14	Thomas Jefferson University	An improved method for design and selection of efficacious antisense oligonucleotides
EP0925289A1 (en)	1997-07-10	1999-06-30	PHARMACIA & UPJOHN S.p.A.	Matrix metalloproteinase inhibitors
DE19731521A1 (en)	1997-07-23	1999-01-28	Byk Gulden Lomberg Chem Fab	Budipin in the treatment of inflammatory diseases of the nervous system
FR2766822B1 (en)	1997-07-30	2001-02-23	Adir	NOVEL DERIVATIVES OF BENZIMIDAZOLE, BENZOXAZOLE AND BENZOTHIAZOLE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR016551A1 (en)	1997-07-30	2001-07-25	Smithkline Beecham Corp	DERIVATIVES OF 2-OXINDOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES
NZ502379A (en)	1997-07-31	2002-10-25	Celgene Corp	Substituted alkanohydroxamic acids and use in pharmaceuticals for reducing TNF-alpha levels
EP1009752B1 (en)	1997-08-04	2007-03-07	Millennium Pharmaceuticals, Inc.	Novel molecules of the tango-77 related protein family and uses thereof
CA2297988A1 (en)	1997-08-04	1999-02-11	Amgen Inc.	Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
ATE217863T1 (en)	1997-08-08	2002-06-15	Pfizer Prod Inc	ARYLSULFONYLAMINOHYDROXAMIC ACID DERIVATIVES
WO1999007679A1 (en)	1997-08-08	1999-02-18	Chiroscience Limited	Peptidyl compounds having mmp and tnf inhibitory activity
IL121860A0 (en)	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use
US5994396A (en)	1997-08-18	1999-11-30	Centaur Pharmaceuticals, Inc.	Furansulfonic acid derivatives and pharmaceutical compositions containing the same
WO1999009965A2 (en)	1997-08-21	1999-03-04	Takeda Chemical Industries, Ltd.	Anti-inflammatory agent
JPH11139994A (en)	1997-10-31	1999-05-25	Kureha Chem Ind Co Ltd	Antitumor agent
CA2308438A1 (en)	1997-11-03	1999-05-14	The Wistar Institute Of Anatomy And Biology	Method and compositions for inhibiting angiogenesis and treating cancer
US5955476A (en)	1997-11-18	1999-09-21	Celgene Corporation	Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
WO1999029865A2 (en)	1997-12-12	1999-06-17	The Rockefeller University	A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
WO1999036415A1 (en)	1998-01-16	1999-07-22	Centaur Pharmaceuticals, Inc.	Thioether furan nitrone compounds
JP2002509153A (en)	1998-01-20	2002-03-26	ワーナー−ランバート・カンパニー	N- [2- (5-benzyloxycarbonyl-amino-6-oxo-2- (4-fluorophenyl) -1,6-dihydro-1-) as an in vivo inhibitor of interleukin-1β converting enzyme (ICE) Pyrimidinyl) acetoxyl] -L-aspartic aldehyde
JP4271850B2 (en)	1998-01-23	2009-06-03	イミュネックス・コーポレーション	IL-18 receptor
ATE301195T1 (en)	1998-01-23	2005-08-15	Immunex Corp	ACPL DNA AND POLYPEPTIDES
EP1051407A1 (en)	1998-01-27	2000-11-15	American Cyanamid Company	2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
EP1053351A4 (en)	1998-01-27	2002-09-25	Millennium Pharm Inc	Novel molecules of the tnf receptor superfamily and uses therefor
DE69925581T2 (en)	1998-03-09	2006-04-27	Vertex Pharmaceuticals Inc., Cambridge	1,2-DIAZEPANDERIVATE AS INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYME
WO1999047154A1 (en)	1998-03-16	1999-09-23	Cytovia, Inc.	Dipeptide caspase inhibitors and the use thereof
IL126024A0 (en)	1998-03-19	1999-05-09	Yeda Res & Dev	Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
BRPI9909660B8 (en)	1998-03-19	2021-05-25	Vertex Pharma	caspase inhibitor compounds, pharmaceutical composition and use of said compounds
ATE317691T1 (en)	1998-03-20	2006-03-15	Daiichi Asubio Pharma Co Ltd	NF-KB INHIBITORS CONTAINING BENZOQUINONE DERIVATIVES
JPH11266872A (en)	1998-03-20	1999-10-05	Suntory Ltd	Screening of substance suppressing activation of nf-kappa b
US6492370B1 (en)	1998-03-26	2002-12-10	Santen Pharmaceutical Co., Ltd.	Urea derivatives and pharmaceutical compositions thereof
EP2009025B1 (en)	1998-05-14	2011-07-27	Immunex Corporation	Method of inhibiting osteoclast activity
HUP0102492A2 (en)	1998-06-19	2001-11-28	Smithkline Beecham Corp.	Use of amino-indanone inhibitors of transcription factor nf-kb for producing pharmaceutical compositions
HUP0102782A3 (en)	1998-06-19	2002-12-28	Smithkline Beecham Corp	Salycilanilide as inhibitors of transcription factor nf-kb
CA2276216A1 (en)	1998-06-24	1999-12-24	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	An artificial peptide capable of neutralizing the biological activity of interleukin-18
US6210924B1 (en)	1998-08-11	2001-04-03	Amgen Inc.	Overexpressing cyclin D 1 in a eukaryotic cell line
EP1110969A4 (en)	1998-09-01	2002-01-09	Hayashibara Biochem Lab	INTERLEUKIN 18 BINDING PROTEIN
ES2239457T3 (en)	1998-09-15	2005-09-16	Pharmexa A/S	PROCEDURE FOR REGULATING LOWER LEADING ACTIVITY OF OSTEOPROTEGERIN.
US6660843B1 (en) *	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
SI2112166T1 (en)	1998-12-23	2019-05-31	Pfizer Inc.	Human monoclonal antibodies to ctla-4
DK1149114T3 (en)	1999-02-03	2014-06-23	Amgen Inc	Polypeptides involved in an immune response
WO2000047740A2 (en)	1999-02-12	2000-08-17	Amgen Inc.	Tnf-related proteins
AUPQ314799A0 (en)	1999-09-29	1999-10-21	University Of Western Australia, The	Bone cell factor
WO2001044472A1 (en)	1999-12-16	2001-06-21	Amgen, Inc.	Tnfr/opg-like molecules and uses thereof
WO2001085782A2 (en)	2000-02-11	2001-11-15	Amgen Inc.	Fusion receptor from tnf family
MXPA02008144A (en) †	2000-02-23	2002-11-29	Amgen Inc	Antagonistic selective binding agents of osteoprotegerin binding protein.
US20030103978A1 (en)	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
AU5943201A (en)	2000-05-03	2001-11-12	Amgen Inc	Modified peptides as therapeutic agents
US7102050B1 (en)	2000-05-04	2006-09-05	Exxonmobil Chemical Patents Inc.	Multiple riser reactor
US20030215450A1 (en) *	2000-05-26	2003-11-20	Blake Simon M	Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US7405734B2 (en) *	2000-07-18	2008-07-29	Silicon Graphics, Inc.	Method and system for presenting three-dimensional computer graphics images using multiple graphics processing units
DE10039710B4 (en)	2000-08-14	2017-06-22	United Monolithic Semiconductors Gmbh	Method for producing passive components on a semiconductor substrate
US20040247596A1 (en) *	2000-08-18	2004-12-09	Odgren Paul R.	TRANCE regulation of chondrocyte differentiation
AU2001288342A1 (en)	2000-08-21	2002-03-04	Smith Kline Beecham Corporation	Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
DE01973455T1 (en)	2000-09-22	2004-04-22	Immunex Corp., Seattle	SCREENING PROCEDURE FOR AGONISTS AND ANTAGONISTS OF THE RECEPTOR ACTIVATOR OF NF-KAPPA B
UY27087A1 (en) *	2001-01-05	2002-06-20	Pfizer	ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR
JP2004536056A (en)	2001-05-17	2004-12-02	イミュネックス・コーポレーション	Therapeutic use of RANK antagonists
EP1432438A2 (en)	2001-06-06	2004-06-30	Immunex Corporation	Use of rank antagonists to treat cancer
DK2270052T3 (en) *	2001-06-26	2018-07-02	Amgen Inc	Antibodies to OPGL
JP4761710B2 (en)	2002-04-05	2011-08-31	アムジェンインコーポレイテッド	Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
WO2013180295A1 (en)	2012-06-01	2013-12-05	日本電信電話株式会社	Packet transfer processing method and packet transfer processing device
US9300829B2 (en)	2014-04-04	2016-03-29	Canon Kabushiki Kaisha	Image reading apparatus and correction method thereof

2002
- 2002-06-25 DK DK10181323.6T patent/DK2270052T3/en active
- 2002-06-25 ES ES18202340T patent/ES2907826T3/en not_active Expired - Lifetime
- 2002-06-25 DK DK10185344.8T patent/DK2295081T3/en active
- 2002-06-25 ME MEP-2008-326A patent/ME00232B/en unknown
- 2002-06-25 SG SG10201603108QA patent/SG10201603108QA/en unknown
- 2002-06-25 TR TR2019/00581T patent/TR201900581T4/en unknown
- 2002-06-25 NZ NZ616594A patent/NZ616594A/en not_active IP Right Cessation
- 2002-06-25 BR BR0210579-9 patent/BRPI0210579B8/en not_active IP Right Cessation
- 2002-06-25 KR KR1020107002067A patent/KR101038585B1/en not_active Expired - Lifetime
- 2002-06-25 IL IL15951202A patent/IL159512A0/en unknown
- 2002-06-25 CA CA2451955A patent/CA2451955C/en not_active Expired - Lifetime
- 2002-06-25 ES ES10181323.6T patent/ES2674888T3/en not_active Expired - Lifetime
- 2002-06-25 CN CN201310052370.5A patent/CN103232539B/en not_active Expired - Lifetime
- 2002-06-25 SG SG2011076551A patent/SG2011076551A/en unknown
- 2002-06-25 ME MEP-326/08A patent/MEP32608A/en unknown
- 2002-06-25 DE DE60235989T patent/DE60235989D1/en not_active Expired - Lifetime
- 2002-06-25 DK DK02749660.3T patent/DK1409016T4/en active
- 2002-06-25 DE DE122010000047C patent/DE122010000047I1/en active Pending
- 2002-06-25 EP EP10185344.8A patent/EP2295081B1/en not_active Expired - Lifetime
- 2002-06-25 NO NO20200535A patent/NO345566B1/en not_active IP Right Cessation
- 2002-06-25 NZ NZ547695A patent/NZ547695A/en not_active IP Right Cessation
- 2002-06-25 ES ES09156995.4T patent/ES2675735T3/en not_active Expired - Lifetime
- 2002-06-25 YU YU103003A patent/YU103003A/en unknown
- 2002-06-25 PH PH1/2012/502439A patent/PH12012502439A1/en unknown
- 2002-06-25 SG SG2005081195A patent/SG173211A1/en unknown
- 2002-06-25 ES ES10185344T patent/ES2706902T3/en not_active Expired - Lifetime
- 2002-06-25 AT AT02749660T patent/ATE464068T1/en active
- 2002-06-25 TR TR2018/09008T patent/TR201809008T4/en unknown
- 2002-06-25 KR KR10-2003-7017009A patent/KR20040023630A/en not_active Ceased
- 2002-06-25 TR TR2018/09678T patent/TR201809678T4/en unknown
- 2002-06-25 WO PCT/US2002/020181 patent/WO2003002713A2/en not_active Ceased
- 2002-06-25 PH PH1/2012/502440A patent/PH12012502440A1/en unknown
- 2002-06-25 EP EP10181323.6A patent/EP2270052B8/en not_active Expired - Lifetime
- 2002-06-25 PT PT101813236T patent/PT2270052T/en unknown
- 2002-06-25 RS RS20120347A patent/RS54274B1/en unknown
- 2002-06-25 CN CNA028166809A patent/CN1547486A/en active Pending
- 2002-06-25 EP EP18202340.8A patent/EP3492100B1/en not_active Expired - Lifetime
- 2002-06-25 PL PL371915A patent/PL222211B1/en unknown
- 2002-06-25 JP JP2003509075A patent/JP4212470B2/en not_active Expired - Lifetime
- 2002-06-25 MX MXPA04000134A patent/MXPA04000134A/en active IP Right Grant
- 2002-06-25 EP EP09156995.4A patent/EP2087908B1/en not_active Expired - Lifetime
- 2002-06-25 EA EA200400063A patent/EA021242B9/en active Protection Beyond IP Right Term
- 2002-06-25 PT PT10185344T patent/PT2295081T/en unknown
- 2002-06-25 ES ES02749660T patent/ES2342820T5/en not_active Expired - Lifetime
- 2002-06-25 EP EP02749660.3A patent/EP1409016B9/en not_active Expired - Lifetime
- 2002-06-25 AU AU2002320157A patent/AU2002320157C1/en not_active Expired
- 2002-06-25 MY MYPI20022368A patent/MY143582A/en unknown
- 2002-06-25 PT PT02749660T patent/PT1409016E/en unknown
- 2002-06-25 DK DK09156995.4T patent/DK2087908T3/en active
- 2002-06-25 US US10/180,648 patent/US7364736B2/en not_active Expired - Lifetime
- 2002-06-25 NZ NZ530765A patent/NZ530765A/en not_active IP Right Cessation
- 2002-06-25 PT PT91569954T patent/PT2087908T/en unknown
- 2002-06-26 TW TW091114055A patent/TWI276443B/en not_active IP Right Cessation
- 2002-06-26 TW TW095103780A patent/TWI326285B/en not_active IP Right Cessation
- 2002-06-26 AR ARP020102401A patent/AR034637A1/en active IP Right Grant
2003
- 2003-12-22 IL IL159512A patent/IL159512A/en active IP Right Grant
2004
- 2004-01-23 ZA ZA200400521A patent/ZA200400521B/en unknown
- 2004-03-10 NO NO20041018A patent/NO343687B1/en not_active IP Right Cessation
2005
- 2005-06-25 NZ NZ581637A patent/NZ581637A/en not_active IP Right Cessation
2007
- 2007-10-30 US US11/981,664 patent/US8058418B2/en not_active Expired - Lifetime
2008
- 2008-07-04 JP JP2008175541A patent/JP4358282B2/en not_active Expired - Lifetime
- 2008-12-19 AU AU2008261137A patent/AU2008261137C1/en not_active Expired
2009
- 2009-07-08 JP JP2009161406A patent/JP4927910B2/en not_active Expired - Lifetime
2010
- 2010-07-08 CY CY20101100637T patent/CY1110196T1/en unknown
- 2010-11-24 CY CY2010016C patent/CY2010016I1/en unknown
- 2010-11-24 LU LU91757C patent/LU91757I2/en unknown
- 2010-11-25 FR FR10C0050C patent/FR10C0050I2/en active Active
2011
- 2011-11-14 US US13/296,201 patent/US8409578B2/en not_active Expired - Fee Related
2012
- 2012-01-17 JP JP2012006740A patent/JP5065529B2/en not_active Expired - Lifetime
- 2012-03-23 JP JP2012066632A patent/JP2012153701A/en not_active Withdrawn
- 2012-07-02 JP JP2012148656A patent/JP5576903B2/en not_active Expired - Lifetime
2013
- 2013-03-14 US US13/831,099 patent/US20140134157A1/en not_active Abandoned
2014
- 2014-10-19 IL IL235116A patent/IL235116A0/en unknown
- 2014-10-28 JP JP2014218929A patent/JP2015057408A/en active Pending
- 2014-11-27 JP JP2014239576A patent/JP2015078205A/en active Pending
2015
- 2015-02-12 US US14/621,072 patent/US20150266952A1/en not_active Abandoned
2016
- 2016-06-07 JP JP2016113389A patent/JP2016216464A/en active Pending
- 2016-09-02 US US15/256,194 patent/US20170183417A1/en not_active Abandoned
2017
- 2017-12-25 JP JP2017247287A patent/JP2018154614A/en not_active Ceased
2018
- 2018-06-26 CY CY181100655T patent/CY1120656T1/en unknown
- 2018-07-17 CY CY181100747T patent/CY1120658T1/en unknown
2019
- 2019-01-21 CY CY20191100079T patent/CY1121151T1/en unknown
- 2019-04-04 NO NO20190456A patent/NO344842B1/en not_active IP Right Cessation
- 2019-06-10 JP JP2019107837A patent/JP2019214563A/en active Pending
- 2019-11-05 NO NO2019039C patent/NO2019039I1/en unknown
- 2019-12-20 NO NO2019048C patent/NO2019048I1/en unknown
- 2019-12-24 JP JP2019232389A patent/JP2020073518A/en active Pending
2020
- 2020-01-09 US US16/738,751 patent/US20200131271A1/en not_active Abandoned
- 2020-06-18 US US16/905,089 patent/US20200354464A1/en not_active Abandoned
2021
- 2021-08-05 JP JP2021128771A patent/JP2022000424A/en active Pending

Also Published As

Publication number	Publication date
TR201809008T4 (en)	2018-07-23
JP2015057408A (en)	2015-03-26
US8409578B2 (en)	2013-04-02
JP2012140430A (en)	2012-07-26
NO345566B1 (en)	2021-04-19
TW200630107A (en)	2006-09-01
ES2342820T5 (en)	2021-04-14
EP2295081B1 (en)	2018-10-31
NZ581637A (en)	2012-05-25
DK2087908T3 (en)	2018-07-23
JP2012153701A (en)	2012-08-16
DE60235989D1 (en)	2010-05-27
ATE464068T1 (en)	2010-04-15
MEP32608A (en)	2011-02-10
NZ530765A (en)	2006-11-30
JP2015078205A (en)	2015-04-23
EP2270052B1 (en)	2018-03-28
LU91757I9 (en)	2019-01-03
CN103232539A (en)	2013-08-07
US7364736B2 (en)	2008-04-29
US20200131271A1 (en)	2020-04-30
NO2019048I1 (en)	2019-12-20
EP3492100A1 (en)	2019-06-05
CY1121151T1 (en)	2020-05-29
JP2020073518A (en)	2020-05-14
US20170183417A1 (en)	2017-06-29
WO2003002713A3 (en)	2003-08-14
EP2087908A1 (en)	2009-08-12
JP2018154614A (en)	2018-10-04
BRPI0210579B1 (en)	2019-05-14
TR201900581T4 (en)	2019-02-21
PH12012502440A1 (en)	2013-06-17
US20140134157A1 (en)	2014-05-15
IL159512A0 (en)	2004-06-01
US20120087923A1 (en)	2012-04-12
DE122010000047I1 (en)	2011-05-05
ES2675735T3 (en)	2018-07-12
SG2011076551A (en)	2015-08-28
JP2016216464A (en)	2016-12-22
JP5065529B2 (en)	2012-11-07
AU2008261137C1 (en)	2023-08-31
EP2270052A2 (en)	2011-01-05
JP2009022280A (en)	2009-02-05
EA021242B9 (en)	2015-11-30
IL235116A0 (en)	2014-11-30
DK2295081T3 (en)	2019-02-18
JP2005506963A (en)	2005-03-10
ES2907826T3 (en)	2022-04-26
AU2002320157C1 (en)	2023-09-21
DK2270052T3 (en)	2018-07-02
RS20120347A2 (en)	2013-04-30
CA2451955A1 (en)	2003-01-09
TR201809678T4 (en)	2018-07-23
CY1110196T1 (en)	2012-01-25
ME00232B (en)	2011-02-10
PL222211B1 (en)	2016-07-29
PL371915A1 (en)	2005-07-11
KR20100041797A (en)	2010-04-22
PH12012502439A1 (en)	2013-06-17
MXPA04000134A (en)	2005-06-06
ZA200400521B (en)	2005-07-27
NZ547695A (en)	2008-09-26
NO20200535A1 (en)	2004-03-10
JP4212470B2 (en)	2009-01-21
CN1547486A (en)	2004-11-17
NO20190456A1 (en)	2004-03-10
NO20041018L (en)	2004-03-10
CY1120658T1 (en)	2019-12-11
NZ616594A (en)	2015-06-26
LU91757I2 (en)	2011-01-24
PT1409016E (en)	2010-06-11
AR034637A1 (en)	2004-03-03
EP1409016A2 (en)	2004-04-21
PT2295081T (en)	2019-02-01
MY143582A (en)	2011-05-31
US20090274688A1 (en)	2009-11-05
BRPI0210579B8 (en)	2021-05-25
US20200354464A1 (en)	2020-11-12
AU2008261137B2 (en)	2012-10-04
TWI326285B (en)	2010-06-21
EP3492100B1 (en)	2021-12-08
EP1409016A4 (en)	2005-11-09
CY1120656T1 (en)	2019-12-11
NO343687B1 (en)	2019-05-06
JP4927910B2 (en)	2012-05-09
EP2087908B1 (en)	2018-05-30
JP2022000424A (en)	2022-01-04
US20150266952A1 (en)	2015-09-24
SG10201603108QA (en)	2016-05-30
CY2010016I2 (en)	2012-01-25
PT2087908T (en)	2018-07-16
CY2010016I1 (en)	2012-01-25
BR0210579A (en)	2005-05-10
AU2002320157B2 (en)	2008-10-16
CN103232539B (en)	2015-06-03
FR10C0050I1 (en)	2011-01-14
AU2008261137A1 (en)	2009-01-15
KR101038585B1 (en)	2011-06-03
JP5576903B2 (en)	2014-08-20
EA200400063A1 (en)	2005-02-24
RS20120347A3 (en)	2013-10-31
NO344842B1 (en)	2020-05-25
NO2019039I1 (en)	2019-11-05
EP2270052A3 (en)	2011-03-02
ES2706902T3 (en)	2019-04-01
KR20040023630A (en)	2004-03-18
JP2009273466A (en)	2009-11-26
ES2342820T3 (en)	2010-07-15
EP2270052B8 (en)	2018-05-02
JP2012229236A (en)	2012-11-22
PT2270052T (en)	2018-07-04
US8058418B2 (en)	2011-11-15
DK1409016T3 (en)	2010-06-21
SG173211A1 (en)	2011-08-29
WO2003002713A2 (en)	2003-01-09
US20040033535A1 (en)	2004-02-19
EP1409016B9 (en)	2020-10-28
DK1409016T4 (en)	2020-09-14
JP4358282B2 (en)	2009-11-04
EP2295081A1 (en)	2011-03-16
HK1187932A1 (en)	2014-04-17
IL159512A (en)	2014-12-31
EP1409016B2 (en)	2020-07-15
ES2674888T3 (en)	2018-07-04
CA2451955C (en)	2015-09-29
JP2019214563A (en)	2019-12-19
EP1409016B1 (en)	2010-04-14
YU103003A (en)	2006-05-25
RS54274B1 (en)	2016-02-29
TWI276443B (en)	2007-03-21
EA021242B1 (en)	2015-05-29

Publication	Publication Date	Title
FR10C0050I2 (en)	2011-12-30	OPGL ANTIBODIES
EP1396500A4 (en)	2005-02-02	ANTI-TRAIL-R ANTIBODIES
EP1423431A4 (en)	2005-04-27	ANTI-VLA-1 ANTIBODIES
EP1378520A4 (en)	2006-08-16	CYCLIC MONOCATARY TRISPECIFIC ANTIBODY
EE200300416A (en)	2003-12-15	Pharmaceutical form
NO20020896L (en)	2003-04-03	Interactive system
EP1383801A4 (en)	2005-06-01	ANTIBODIES AGAINST CANCER
ATE335486T1 (en)	2006-09-15	HYDRAZONO-MALONITRILE
EE200300569A (en)	2004-04-15	CD44v6-specific antibodies
DE60208631D1 (en)	2006-04-06	Pedal support structure
DE60110029D1 (en)	2005-05-19	paperfeeding
EE200300480A (en)	2003-12-15	Pregabalin-lactose conjugates
NO20016009D0 (en)	2001-12-07	Navigation Concept
ATE369137T1 (en)	2007-08-15	LYOPHILIZED FORMULATION CONTAINING OLNZAPINE
DE50211902D1 (en)	2008-04-30	system part
DE60214042D1 (en)	2006-09-28	WET-DRY-CLEANING SYSTEM
DE50208629D1 (en)	2006-12-21	pedal
ATA18372001A (en)	2005-07-15	GELENKSBOLZENBAUEINHEIT
DE50207829D1 (en)	2006-09-28	pedal
ATE319694T1 (en)	2006-03-15	PHENYLALKYNE
DE60237655D1 (en)	2010-10-28	processor
DE60229395D1 (en)	2008-11-27	TION
DE50212042D1 (en)	2008-05-21	pedal
ATE405973T1 (en)	2008-09-15	CONNECTION
AT500276B1 (en)	2006-06-15	RADSCHWENKSYSTEM